Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Cash (2016 - 2025)

Historic Change in Cash for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $651000.0.

  • Pharma's Change in Cash rose 33417.27% to $651000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$441000.0, marking a year-over-year increase of 7020.27%. This contributed to the annual value of -$793000.0 for FY2025, which is 6031.03% up from last year.
  • As of Q3 2025, Pharma's Change in Cash stood at $651000.0, which was up 33417.27% from $49000.0 recorded in Q2 2025.
  • Pharma's Change in Cash's 5-year high stood at $13.6 million during Q1 2021, with a 5-year trough of -$2.5 million in Q4 2021.
  • In the last 5 years, Pharma's Change in Cash had a median value of -$1.1 million in 2024 and averaged $7210.5.
  • Data for Pharma's Change in Cash shows a peak YoY increase of 57300.59% (in 2021) and a maximum YoY decrease of 124316.94% (in 2021) over the last 5 years.
  • Over the past 5 years, Pharma's Change in Cash (Quarter) stood at -$2.5 million in 2021, then surged by 31.73% to -$1.7 million in 2022, then rose by 1.79% to -$1.6 million in 2023, then skyrocketed by 34.71% to -$1.1 million in 2024, then skyrocketed by 160.5% to $651000.0 in 2025.
  • Its last three reported values are $651000.0 in Q3 2025, $49000.0 for Q2 2025, and -$65000.0 during Q1 2025.